Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation.

den Brok MH, Büll C, Wassink M, de Graaf AM, Wagenaars JA, Minderman M, Thakur M, Amigorena S, Rijke EO, Schrier CC, Adema GJ.

Nat Commun. 2016 Nov 7;7:13324. doi: 10.1038/ncomms13324.

2.

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P.

Ann Oncol. 2016 Oct;27(10):1947-53. doi: 10.1093/annonc/mdw291. Epub 2016 Aug 8.

3.

Vaccine adjuvants as potential cancer immunotherapeutics.

Temizoz B, Kuroda E, Ishii KJ.

Int Immunol. 2016 Jul;28(7):329-38. doi: 10.1093/intimm/dxw015. Epub 2016 Mar 22. Review.

4.

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW.

Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18.

5.

Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E.

Hao J, Song X, Wang J, Guo C, Li Y, Li B, Zhang Y, Yin Y.

Oncotarget. 2015 Dec 8;6(39):42028-39. doi: 10.18632/oncotarget.5973.

6.

Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.

Lu W, Qiu L, Yan Z, Lin Z, Cao M, Hu C, Wang Z, Wang J, Yu Y, Cheng X, Cao P, Li R.

Oncotarget. 2015 Oct 27;6(33):34537-48. doi: 10.18632/oncotarget.5307.

7.

Vaccine Potentiation by Combination Adjuvants.

Levast B, Awate S, Babiuk L, Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S.

Vaccines (Basel). 2014 Apr 14;2(2):297-322. doi: 10.3390/vaccines2020297. Review.

8.

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors.

Gérard C, Baudson N, Ory T, Segal L, Louahed J.

J Immunother. 2015 Oct;38(8):311-20. doi: 10.1097/CJI.0000000000000095.

9.

Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.

Reed CM, Cresce ND, Mauldin IS, Slingluff CL Jr, Olson WC.

Clin Cancer Res. 2015 Sep 1;21(17):3879-87. doi: 10.1158/1078-0432.CCR-15-0233. Epub 2015 May 12.

10.

Trial Watch: Toll-like receptor agonists in oncological indications.

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Aug 1;3:e29179. eCollection 2014 Aug 1.

11.

Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.

Gérard C, Baudson N, Ory T, Louahed J.

PLoS One. 2014 May 15;9(5):e94883. doi: 10.1371/journal.pone.0094883. eCollection 2014 May 15.

12.

Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.

Cheng WF, Chang MC, Sun WZ, Jen YW, Liao CW, Chen YY, Chen CA.

PLoS One. 2013 Sep 13;8(9):e71216. doi: 10.1371/journal.pone.0071216. eCollection 2013 Sep 13.

13.
14.

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Oncoimmunology. 2012 Sep 1;1(6):894-907.

15.

B cell TLRs and induction of immunoglobulin class-switch DNA recombination.

Pone EJ, Xu Z, White CA, Zan H, Casali P.

Front Biosci (Landmark Ed). 2012 Jun 1;17:2594-615. Review.

16.

Adjuvant therapy for melanoma.

Davar D, Tarhini AA, Kirkwood JM.

Cancer J. 2012 Mar-Apr;18(2):192-202. doi: 10.1097/PPO.0b013e31824f118b. Review.

17.

TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.

Straetemans T, van Brakel M, van Steenbergen S, Broertjes M, Drexhage J, Hegmans J, Lambrecht BN, Lamers C, van Der Bruggen P, Coulie PG, Debets R.

Clin Dev Immunol. 2012;2012:586314. doi: 10.1155/2012/586314. Epub 2012 Feb 12.

18.

Adjuvant therapy: melanoma.

Davar D, Tarhini A, Kirkwood JM.

J Skin Cancer. 2011;2011:274382. doi: 10.1155/2011/274382. Epub 2011 Dec 19.

19.

TLR-based immune adjuvants.

Steinhagen F, Kinjo T, Bode C, Klinman DM.

Vaccine. 2011 Apr 12;29(17):3341-55. doi: 10.1016/j.vaccine.2010.08.002. Epub 2010 Aug 14. Review.

20.

Optimized subunit vaccine protects against experimental leishmaniasis.

Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, Coler RN, Vedvick TS, Reed SG.

Vaccine. 2009 Nov 23;27(50):7036-45. doi: 10.1016/j.vaccine.2009.09.066. Epub 2009 Sep 26.

Supplemental Content

Support Center